Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $85.42, for a total value of $392,932.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.37, for a total transaction of $631,738.00.

Kymera Therapeutics Price Performance

KYMR stock traded down $0.16 during trading on Thursday, reaching $84.77. 114,596 shares of the company were exchanged, compared to its average volume of 761,006. The company has a market capitalization of $6.92 billion, a price-to-earnings ratio of -23.04 and a beta of 2.20. The company has a 50-day moving average of $81.01 and a two-hundred day moving average of $71.64. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same period in the previous year, the firm posted ($0.88) EPS. The business’s quarterly revenue was down 60.8% compared to the same quarter last year. On average, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on KYMR shares. Stifel Nicolaus set a $114.00 target price on shares of Kymera Therapeutics in a research report on Monday, December 8th. Truist Financial lifted their price target on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. BTIG Research decreased their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Wells Fargo & Company raised their target price on Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Finally, Wall Street Zen lowered Kymera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $118.90.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its holdings in Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC increased its holdings in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. lifted its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the period. Finally, Bessemer Group Inc. boosted its holdings in shares of Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.